PPD is working to get therapeutic area experts into its highest offices, poaching UCB's former head of immunology to lead its efforts in the field.
PPD has acquired Pennsylvania's Acurian, folding the company's clinical trial patient enrollment and retention services into its expanding eClinical operation.
China has fast become a huge pillar on the global R&D scene, with local CROs like WuXi PharmaTech and ShangPharma cashing in on demand for clinical trials in the country. But, with the FDA chiding a sloppy Chinese trial run by Bristol-Myers Squibb, Pfizer and PPD, regulators and researchers may think twice before accepting data gathered in the country.
BOSTON-- Walking through the annual Drug Information Association meeting, you can't miss the signs of consolidation, from the HCR tacked onto Synteract's logo to the buzz around PRA's corner of the conference when attendees found out it was soon to change hands for $1.3 billion. Read the feature >>
BioDuro, PPD's China-based drug discovery business, has opened a state-of-the-art facility in Shanghai, a lab the company says will help it cozy up to clients in the growing Asian biopharmaceutical world.
Up until now, the FDA has reserved its new "breakthrough" designation for a Who's Who in drug development, with high-profile companies like J&J, Merck and Novartis touting their scores at the agency. But now the FDA has delivered the coveted designation to Durham, NC-based ScioDerm, a little-known start-up that just landed its Series A of $16 million. And its success is blazing a path others can follow.
As clinical trials get more and more complex, Pharmaceutical Product Development has reached out to technology consultancies Tessella and Berry Consultants to use FACTS, adaptive trial software that lets study designers simulate trials in their early planning stages.
As drug developers seek efficient ways to study new treatments for complex disease, Pharmaceutical Product Development has tapped adaptive clinical trials software from technology consultancies Tessella and Berry Consultants.
At DIA in Philadelphia this week, high-level representatives from CROs sat down for a roundtable discussion with Pharmalot blogger Ed Silverman to discuss the future of CROs and what needs to be done in partnering, innovation and efficacy.
David Simmons, a former Pfizer executive and general manager, will join Pharmaceutical Product Development as its new Chairman and CEO June 4.